|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 411 Swedeland Road |
Address2 | Suite 23-1080 |
| City | King of Prussia |
State | PA |
Zip Code | 19406 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105511-12
|
||||||||
|
6. House ID# 446430001
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Lara Flynn |
Date | 4/21/2025 5:24:07 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Pennsylvania is a global leader in researching and developing new therapies, cures, and devices that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.
Life Sciences PA works annually with its Federal Policy Committee and national partners to develop a set of policy issues and recommendations that will support and enhance the countrys life sciences ecosystem and maintains Pennsylvanias leadership in life sciences innovation.
As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Pennsylvania is a global leader in researching and developing new therapies, cures, and devices that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.
Life Sciences PA works annually with its Federal Policy Committee and national partners to develop a set of policy issues and recommendations that will support and enhance the countrys life sciences ecosystem and maintains Pennsylvanias leadership in life sciences innovation.
As the statewide Trade Association for the Life Sciences, our Public Policy advocacy work remains to engage and educate the Pennsylvania Congressional Delegation to incentivize innovation and protect patient access.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.
In 2023, Pennsylvania research institutions and small companies received more than $2 billion in NIH funding. This critical funding provides our ecosystem with foundational resources for biomedical innovation. It is complemented by significant private funding necessary to advance basic scientific research into safe, usable, and effective medicines. In fact, a 2022 report found that [private]industry accounts for nearly two-thirds of U.S. medical and health investment in R&D and the Federal government investment accounts for one-quarter (25%) of all U.S. medical and health R&D
As a critical component of this ecosystem, it is essential we continue to expand support for the National Institutes of Health to ensure the United States - and Pennsylvania - remain a global leader in researching and developing new therapies, cures, and technologies that help patients live longer, healthier lives. Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. Specifically, we encourage our membership to contact their members of Congress through our Advocacy Action Center regarding the newly announced15% indirect cost rate that immediately applies to all new and existing NIH grants.
The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Reauthorization
Innovative research and the development of groundbreaking medicines, therapeutics and diagnostics is a top priority for life science companies throughout Pennsylvania. These innovations require an abundance of resources, which is why support at both the federal and state levels is important. Many of these companies rely on SBIR (Small Business Innovation Research) funds as a critical component to moving their work forward. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs help translate cutting-edge discoveries into real-world solutions - driving economic growth, creating jobs, and improving public health. These programs are currently scheduled to expire September 30, 2025.
Life Sciences PA supports the permanent reauthorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, created in 1982 and 1992, respectively. While not life sciences specific, these two programs fund domestic small businesses engaging in research and development on the path to technology commercialization. In 2021, the SBIR program funded more than $30 million in life sciences research in Pennsylvania. This funding has helped many of our small member companies grow and thrive.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Previously, Section 174 of the US Tax code allowed businesses to deduct research and experimentation expenses in the same taxable year in which they occurred. Currently, businesses must amortize such deductions over five years for domestic expenditures or over 15 years for foreign expenditures.
Life Sciences Pennsylvania supports the American Innovation and R&D Competitiveness Act which will fix this issue that adversely affects adversely affects many of our pre-revenue and early stage member companies. In a bipartisan manner, the majority of the Pennsylvania delegation has previously voted in favor of the repeal of Section 174 so that smaller companies can resume investing maximal resources in critical R&D.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Pennsylvania is a global leader in researching and developing new therapies, devices and diagnostics that help patients live longer, healthier lives. This innovation is due in part to the policy and regulatory ecosystem we enjoy in the United States.
In 2023, Pennsylvania research institutions and small companies received more than $2 billion in NIH funding. This critical funding provides our ecosystem with foundational resources for biomedical innovation. It is complemented by significant private funding necessary to advance basic scientific research into safe, usable, and effective medicines. In fact, a 2022 report found that [private]industry accounts for nearly two-thirds of U.S. medical and health investment in R&D and the Federal government investment accounts for one-quarter (25%) of all U.S. medical and health R&D
As a critical component of this ecosystem, it is essential we continue to expand support for the National Institutes of Health to ensure the United States - and Pennsylvania - remain a global leader in researching and developing new therapies, cures, and technologies that help patients live longer, healthier lives. Life Sciences PA supports a robust NIH budget as well as opportunities for Pennsylvania to maintain its leadership role with continued collaborative grant support including the DOD, EDA and NSF. Specifically, we encourage our membership to contact their members of Congress through our Advocacy Action Center regarding the newly announced15% indirect cost rate that immediately applies to all new and existing NIH grants.
The NIH is the leading investor worldwide in basic scientific research. This funding supports the crucial first step in life sciences investment through discovery and understanding of human biology and physiology. Pennsylvania research institutions and small companies received more than $2 billion in NIH funding in 2023 and, in many cases, hold contractual agreements with the NIH. This research also leads to spin-out companies and technology transfer that perpetuate the cycle of innovation in the Commonwealth. This cut threatens continued research and development in potential treatments and cures for patients
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Strong intellectual property protections are the foundation for innovation in the life sciences. The U.S. patent system, though now ranked 12th worldwide by the U.S. Chamber of Commerce, maintains important protections for companies researching and developing new medicines and technologies. These protections are especially important for the many small life sciences companies that call Pennsylvania home, and for the technology transfer offices that many of our academic institutions operate to move inventions from the lab to widely available treatments and cures for patients.
The University and Small Business Patent Procedures Act Of 1980, more commonly called the Bayh-Dole Act, provides recipients of federal research funding the right to retain ownership of the inventions that were conceived or first actually reduced to practice under their federal funding agreements. Intended to promote utilization of inventions arising from federally supported R&D and increase the number of inventions that progressed from the laboratories into the marketplace.
Four decades on, changes to these policies would dramatically disrupt the already fragile ecosystem of academic research institutions, industry partners as well as private investment into treatments that have the potential to extend life expectancy in patients. This does not accurately account for the significant time and resources private investment organizations and companies make to research and develop safe, effective, and usable medicines.
Life Sciences Pennsylvania and the academic research institutions as well as R&D based companies that call Pennsylvania home, understand the importance of the strong intellectual property protections that we have in the U.S. Exercising march-in rights will significantly disrupt an innovation ecosystem that already faces challenging odds developing novel therapies and technologies for unmet medical needs.
Life Sciences Pennsylvania joins the Partnership for the U.S. Life Science Ecosystem (PULSE) in sharing the unique nature of mergers and acquisitions (M&A) within our membership. To successfully bring cutting edge breakthroughs from bench to bedside-from the earliest NIH funded research in the academic setting through large scale manufacturing, mergers and acquisitions are a cornerstone of the American success of innovation. DOJ and FTC regulatory changes should be nuanced in this space.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Its important that when discussing patient access, we also highlight the drug pricing supply chain in the United States. While much attention is focused on the cost of prescription medicines, which account for approximately 10-14% of nationwide health care costs - a number thats remained consistent for decades - the real issue is the out-of-pocket costs borne by patients.
The cost of medicines is the cause of much debate by the public and elected officials and determining who pays for what medicines and at what cost is an important discussion to have. Life Sciences PA believes all parts - pharmacy benefit managers (PBMs), health insurance companies, pharmacies, healthcare providers, distributors and manufacturers - of our complex drug pricing system have a role to play in this debate. It is incumbent upon all of us to ensure that all parts of the prescription drug supply chain are acting in good faith and working to keep costs, especially those out-of-pocket costs borne by the patient, at an accessible level.
Life Sciences PA is committed to educating legislators on how insurance benefit design and various actors in the drug pricing supply chain can affect the out-of-pockets costs patients pay at the pharmacy. As noted above, the drug pricing, payment and distribution system is complex and includes many stakeholders. Life Sciences PA believes that all those stakeholders must be included in any, and all, discussions around lowering the cost of prescription medicines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lara |
Flynn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |